Responses
Clinical/translational cancer immunotherapy
Original research
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Compose a Response to This Article
Other responses
No responses have been published for this article.
